The U.S. Food and Drug Administration has approved a new indication for Cytalux (pafolacianine) to assist surgeons in identifying lung cancer lesions in adult patients with known or suspected lung cancer. Cytalux is designed to improve the ability to locate additional lung cancerous tissue that are normally difficult to detect during surgery. The drug is a diagnostic agent that is administered in the form of an intravenous injection prior to surgery.
The U.S. Food and Drug Administration has approved a new indication for Cytalux (pafolacianine) to assist surgeons in identifying lung cancer lesions in adult patients with known or suspected lung cancer. Cytalux is designed to improve the ability to locate additional lung cancerous tissue that are normally difficult to detect during surgery. The drug is a diagnostic agent that is administered in the form of an intravenous injection prior to surgery.